References
- Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007;45(Suppl S):S5-67. https://doi.org/10.1016/j.jvs.2006.12.037
- Creager MA, Kaufman JA, Conte MS. Clinical practice. Acute limb ischemia. N Engl J Med 2012;366:2198-206. https://doi.org/10.1056/NEJMcp1006054
- Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354. https://doi.org/10.1161/circ.114.4.257
- Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, Santini M, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008;29:1181-9. https://doi.org/10.1093/eurheartj/ehn139
- Andersen LV, Lip GY, Lindholt JS, Frost L. Upper limb arterial thromboembolism: a systematic review on incidence, risk factors, and prognosis, including a meta-analysis of risk-modifying drugs. J Thromb Haemost 2013;11:836-44. https://doi.org/10.1111/jth.12181
- Andersen LV, Mortensen LS, Lindholt JS, Faergeman O, Henneberg EW, Frost L. Upper-limb thrombo-embolectomy: national cohort study in Denmark. Eur J Vasc Endovasc Surg 2010;40:628-34. https://doi.org/10.1016/j.ejvs.2010.06.009
- Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. https://doi.org/10.1056/NEJMoa0905561
- Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17. https://doi.org/10.1056/NEJMoa1007432
- Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding:a systematic review and meta-analysis. Eur Heart J 2016;37:1591-602. https://doi.org/10.1093/eurheartj/ehw007
- Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation:incidence and predictors during aspirin therapy. J Am Coll Cardiol 2000;35:183-7. https://doi.org/10.1016/S0735-1097(99)00489-1
- Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007;50:2156-61. https://doi.org/10.1016/j.jacc.2007.07.076
- Andersen LV, Vestergaard P, Deichgraeber P, Lindholt JS, Mortensen LS, Frost L. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation:a meta-analysis. Heart 2008;94:1607-13. https://doi.org/10.1136/hrt.2007.135657
- Geller BJ, Giugliano RP, Braunwald E, Murphy SA, Hanyok JJ, Jin J, et al. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. Am Heart J 2015;170:669-74. https://doi.org/10.1016/j.ahj.2015.06.020